Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Protein–Protein Interactions: New Perspectives in Drug Discovery
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Protein–Protein Interactions: New Perspectives in Drug Discovery

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Biology".

Deadline for manuscript submissions: 20 January 2025 | Viewed by 8583

Special Issue Editor

Dr. Tibor Szénási

E-Mail Website
Guest Editor
Institute of Enzymology, Research Centre for Natural Sciences, ELKH, 1117 Budapest, Hungary
Interests: cytoskeleton; GPCR; protein–protein interaction; Parkinson’s disease; cancer

Special Issue Information

Dear Colleagues,

The present Special Issue entitled “Protein–Protein Interactions: New Perspectives in Drug Discovery” aims to show new perspectives, new interactions, drug targets, and draw attention to drug development directions. All new articles describing protein–protein interactions and manuscripts defining negative protein–protein interactions as drug targets are welcome in the special section. Whether the method is a new approach or the use of small molecules, peptides, nucleotide aptamers, protein–protein interactions influencing cell division, cell proliferation, proteinopathy cancer processes or G-protein-coupled receptors and other receptor-ligand and signal transduction pathways. IJMS is a journal of molecular science, so pure clinical studies are not suitable for a journal. This Special Issue however, it welcomes submissions of clinical or pure models related to biomolecular experiments.

Dr. Tibor Szénási
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • small molecule
  • proteinopathy
  • cancer
  • aptamer
  • drug target

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 4367 KiB  
Article
BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis
by Ziying Zhou, Chenxi Zhao, Siyan Li, Xiaoyang Han, Jiangyi Zhu, Situ Xue and Zhuorong Li
Int. J. Mol. Sci. 2024, 25(6), 3350; https://doi.org/10.3390/ijms25063350 - 15 Mar 2024
Viewed by 1425
Abstract
As the global population ages, the number of patients with osteoporosis is rapidly rising. The existing first-line clinical drugs are bone resorption inhibitors that have difficulty restoring the bone mass of elderly patients to the safe range. The range and period of use [...] Read more.
As the global population ages, the number of patients with osteoporosis is rapidly rising. The existing first-line clinical drugs are bone resorption inhibitors that have difficulty restoring the bone mass of elderly patients to the safe range. The range and period of use of existing peptides and monoclonal antibodies are limited, and small-molecule bone formation–promoting drugs are urgently required. We established an I-9 synthesis route with high yield, simple operation, and low cost that was suitable for future large-scale production. I-9 administration promoted bone formation and increased bone mass in mice with low bone mass in an aged C57 mouse model. Our findings revealed a hitherto undescribed pathway involving the BMP2–ERK–ATF4 axis that promotes osteoblast differentiation; I-9 has favorable biosafety in mice. This study systematically investigated the efficacy, safety, and mechanism of I-9 for treating osteoporosis and positions this drug for preclinical research in the future. Thus, this study has promoted the development of small-molecule bone-promoting drugs. Full article
(This article belongs to the Special Issue Protein–Protein Interactions: New Perspectives in Drug Discovery)
►▼ Show Figures

Figure 1

17 pages, 6917 KiB  
Article
Andrographolide Alleviates Oxidative Damage and Inhibits Apoptosis Induced by IHNV Infection via CTSK/BCL2/Cytc Axis
by Qi Liu, Linfang Li, Jingzhuang Zhao, Guangming Ren, Tongyan Lu, Yizhi Shao and Liming Xu
Int. J. Mol. Sci. 2024, 25(1), 308; https://doi.org/10.3390/ijms25010308 - 25 Dec 2023
Cited by 1 | Viewed by 1474
Abstract
Infectious hematopoietic necrosis virus (IHNV) is an important pathogen that causes significant economic losses to salmon trout farming. Although vaccines have been invented for the treatment of IHNV, findings from our previous survey show that breeding enterprises and farmers require effective oral drugs [...] Read more.
Infectious hematopoietic necrosis virus (IHNV) is an important pathogen that causes significant economic losses to salmon trout farming. Although vaccines have been invented for the treatment of IHNV, findings from our previous survey show that breeding enterprises and farmers require effective oral drugs or immune enhancers. However, studies on the development of oral drugs are limited. In the present study, we used bioinformatics methods to predict the protein targets of andrographolide (Andro) in IHNV. Cells were infected with IHNV, and the effect of andrographolide was explored by evaluating the expression levels of genes implicated in oxidative stress, activities of antioxidant enzymes, and the expression of genes implicated in apoptosis and necrosis. In the present study, cells were divided into NC, IHNV, IHNV+10 μM andrographolide, and IHNV+20 μM andrographolide groups. qRT-PCR was performed to determine the expression level of genes, and an antioxidant enzyme detection kit was used to evaluate the activities of antioxidant enzymes. Fluorescent staining was performed using a reactive oxygen species detection kit (ROS) and Hoechst 33342/PI double staining kit, and the mechanism of alleviation of apoptosis and oxidative stress andrographolide after IHNV infection was determined. The results indicated that andrographolide inhibits viral growth by binding to the NV protein of IHNV and increasing the antioxidant capacity of the body through the CTSK/BCL2/Cytc axis, thereby inhibiting the occurrence of IHNV-induced apoptosis. This is the first study to explore the antagonistic mechanism of action of andrographolide in alleviating IHNV infection. The results provide valuable information on alternative strategies for the treatment of IHNV infection during salmon family and provide a reference for the use of andrographolide as an antioxidant agent in agricultural settings. Full article
(This article belongs to the Special Issue Protein–Protein Interactions: New Perspectives in Drug Discovery)
►▼ Show Figures

Figure 1

12 pages, 1269 KiB  
Article
In Vitro Analysis of SARS-CoV-2 Spike Protein and Ivermectin Interaction
by Alejandra García-Aguilar, Rebeca Campi-Caballero, Giovani Visoso-Carvajal, José Rubén García-Sánchez, José Correa-Basurto, Jazmín García-Machorro and Judith Espinosa-Raya
Int. J. Mol. Sci. 2023, 24(22), 16392; https://doi.org/10.3390/ijms242216392 - 16 Nov 2023
Viewed by 3257
Abstract
The spike (S) protein of SARS-CoV-2 is a molecular target of great interest for developing drug therapies against COVID-19 because S is responsible for the interaction of the virus with the host cell receptor. Currently, there is no outpatient safety treatment for COVID-19 [...] Read more.
The spike (S) protein of SARS-CoV-2 is a molecular target of great interest for developing drug therapies against COVID-19 because S is responsible for the interaction of the virus with the host cell receptor. Currently, there is no outpatient safety treatment for COVID-19 disease. Furthermore, we consider it of worthy importance to evaluate experimentally the possible interaction of drugs (approved by the Food and Drug Administration) and the S, considering some previously in silico and clinical use. Then, the objective of this study was to demonstrate the in vitro interaction of ivermectin with S. The equilibrium dialysis technique with UV–Vis was performed to obtain the affinity and dissociation constants. In addition, the Drug Affinity Responsive Target Stability (DARTS) technique was used to demonstrate the in vitro interaction of S with ivermectin. The results indicate the interaction between ivermectin and the S with an association and dissociation constant of Ka = 1.22 µM−1 and Kd = 0.81 µM, respectively. The interaction was demonstrated in ratios of 1:50 pmol and 1:100 pmol (S: ivermectin) by the DARTS technique. The results obtained with these two different techniques demonstrate an interaction between S and ivermectin previously explored in silico, suggesting its clinical uses to stop the viral spread among susceptible human hosts. Full article
(This article belongs to the Special Issue Protein–Protein Interactions: New Perspectives in Drug Discovery)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1694 KiB  
Review
Connective Tissue Growth Factor: Regulation, Diseases, and Drug Discovery
by Meishen Ren, Shanshan Yao, Tienan Chen, Hang Luo, Xiaohui Tao, Hewen Jiang, Xin Yang, Huarui Zhang, Sifan Yu, Yin Wang, Aiping Lu and Ge Zhang
Int. J. Mol. Sci. 2024, 25(9), 4692; https://doi.org/10.3390/ijms25094692 - 25 Apr 2024
Viewed by 1684
Abstract
In drug discovery, selecting targeted molecules is crucial as the target could directly affect drug efficacy and the treatment outcomes. As a member of the CCN family, CTGF (also known as CCN2) is an essential regulator in the progression of various diseases, including [...] Read more.
In drug discovery, selecting targeted molecules is crucial as the target could directly affect drug efficacy and the treatment outcomes. As a member of the CCN family, CTGF (also known as CCN2) is an essential regulator in the progression of various diseases, including fibrosis, cancer, neurological disorders, and eye diseases. Understanding the regulatory mechanisms of CTGF in different diseases may contribute to the discovery of novel drug candidates. Summarizing the CTGF-targeting and -inhibitory drugs is also beneficial for the analysis of the efficacy, applications, and limitations of these drugs in different disease models. Therefore, we reviewed the CTGF structure, the regulatory mechanisms in various diseases, and drug development in order to provide more references for future drug discovery. Full article
(This article belongs to the Special Issue Protein–Protein Interactions: New Perspectives in Drug Discovery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop